linjc16/ctgov huggingface dataset:
Motexafin Gadolinium With Chemotherapy and Radiation Therapy for the Treatment of Advanced Head and Neck Cancer

Study Overview
=================
Brief Summary
-----------------
The purpose of this study is to evaluate the safety of adding the investigational drug Motexafin Gadolinium to the standard treatment of radiation therapy and chemotherapy with drugs called 5-FU and cisplatin in patients with advanced head and neck cancer.

Official Title
-----------------
Phase I Trial of Motexafin Gadolinium and Chemoradiation in Locally Advanced, Squamous Cell Carcinoma of the Head and Neck

Conditions
-----------------
Head and Neck Cancer, Oropharynx Cancer, Larynx Cancer, Hypopharynx Cancer

Intervention / Treatment
-----------------
* Drug: Motexafin Gadolinium Injection


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: At least 18 years of age Each patient must sign a study-specific informed consent form Newly diagnosed, locally advanced, non-metastatic Squamous Cell Carcinoma of the Head and Neck (SCCHN) arising from a primary site in the oropharynx, hypopharynx, or larynx confirmed by evaluation of fine needle aspiration or biopsy samples and MRI Eligible for curative intent treatment with hyperfractionated radiation and concurrent 5-FU and cisplatin Karnofsky Performance Status score of at least 60% Primary tumor at least 4 cm in diameter Exclusion Criteria: Laboratory Values of: Serum creatinine > 1.8 mg/dL; unless 24-hour urine creatinine clearance is ≥ 70 mL/min Serum total bilirubin > 1.5 times the upper limit of normal ALT (formerly SGPT) > 1.5 times the upper limit of normal Alkaline phosphatase > 1.5 times the upper limit of normal Absolute neutrophil count (ANC) < 1500/L Platelet count < 100,000/L 3+ or greater proteinuria on urinalysis and Squamous Cell Carcinoma of the Head and Neck arising from a primary site in the oral cavity or nasopharynx Distant metastases Prior history of cancer at any site treated with radiotherapy and/or chemotherapy History of SCCHN diagnosed within 5 years of current diagnosis

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Non-Randomized
Intervention Model: Single Group Assignment
Masking: None (Open Label)


Arms and Interventions

| Intervention/Treatment |
| --- |
|Drug: Motexafin Gadolinium Injection|nan|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Head and Neck Cancer, SCCHN, Oropharynx Cancer, Hypopharynx Cancer, Larynx Cancer, Soft palate Cancer, Tonsil Cancer, Base of tongue Cancer, Supraglottic Cancer, Glottic Cancer, Pyriform Sinus Cancer, Pharyngeal wall Cancer, Throat cancer
Acoustic Radiation Force Impulse (ARFI)Technology in Prediction of Liver Fibrosis

Study Overview
=================
Brief Summary
-----------------
Background: In patients with chronic liver diseases, liver fibrosis staging is crucial for hazard evaluation of future disease complication development and thus for the optimal decision making on treatment selections.In the era of antiviral and antifibrotic treatments, clinical and research demands are also increasing for non-invasive surveillance of liver fibrosis to evaluate the progression or regression. However, local baseline data on liver stiffness measurement (LSM) using ARFI technique is still lacking in Taiwan, where viral hepatitides are highly endemic. Aim: Using the ARFI elastosonography, we are dedicated to the aims to recruit patients based on strict but appropriate criteria, to complete the correlation and validity studies between ARFI quantification and the referenced METAVIR fibrosis scoring and to conduct subsequent innovative studies on liver diseases. Materials and Methods: We plan to perform the ARFI quantification for each HBV or HCV-infected patient immediately followed by priorly scheduled conventional liver biopsy for METAVIR scoring during the same session of examination. Statistics: The first year's study using ARFI will focus on the correlation testings and validity studies using receiver operating characteristics.

Detailed Description
-----------------
Contribution and Future Works: Using the ARFI quantification either as a causal factor or as a outcome, we can conduct future analyses ranging from validations, regressions to prospective time-to-event analysis among our cohorts.

Official Title
-----------------
Clinical Application of Acoustic Radiation Force Impulse (ARFI)Technology in Prediction of Liver Fibrosis in HBV and HCV-infected Patients

Conditions
-----------------
Liver Fibrosis

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: infected with HBV only or HCV only Exclusion Criteria: concurrent HBV-HCV infection, etc.

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 75 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| HBV-infected<br> | |
| HCV-infected<br> | |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Acoustic Radiation Force Impulse (ARFI), Virtual Touch Quantification (VTQ), liver stiffness measurement (LSM), liver fibrosis, cirrhosis, hepatitis B, hepatitis C
Sternal ECG Patch Comparison Trial

Study Overview
=================
Brief Summary
-----------------
This study is intended to compare the new Carnation Ambulatory Monitoring (CAM) System, a patch monitoring system, with the Holter monitoring system. Holters represent the current standard for continuous recording of the ECG over extended periods.

Detailed Description
-----------------
The purpose of this research is to simplify the system of recording ECGs. Carnation Ambulatory Monitoring (CAM) System is a small patch system that can be worn during most activities include showering. Each patient will be his or her own control, and will wear the CAM and Holter systems simultaneously for 24 hours. Both systems will then be sent out for analysis.

Official Title
-----------------
Comparison of a Sternal ECG Patch With a Standard Recording System for Holter Monitoring

Conditions
-----------------
Syncope, Presyncope, Palpitations, Atrial Fibrillation, Supraventricular Tachycardia

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Syncope of uncertain etiology or Pre-syncope of uncertain etiology or Palpitations of uncertain etiology or Management of known AF/SVT patients Exclusion Criteria: Any dermatitis or infected skin over the sternum (Carnation patch) or left upper anterior thorax (Zio patch). A sternal or thoracic incision that extends under the patch within 3 months from the date of enrollment

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------
What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| ECG signal quality | ECG signal quality = scoring the ability of each system to record electrical activity from the atrium (P-waves). The Physician Event Committee will independently score the P-waves from all recordings, using the following scale: Excellent, Good, Fair, Poor, Non-existent. Diagnostic yield will also be assessed. | 24 hours of patient use, plus shipping and analysis time   2 weeks | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Device comfort | Secondary outcome measures will include Human Factors performance of the 2 systems, which will be scored and compared in the following areas and duration of patch adherence: skin irritation, comfort, contact and stability. | 24 hours |
Ultrasound Guided Central Vein Catheterization and Complications

Study Overview
=================
Brief Summary
-----------------
There has been no study comparing the complication rates between internal jugular vein catheterization and subclavian vein catheterization when they are performed using sonographic view. This prospective study would reveal the sort of complication and its rate.

Official Title
-----------------
Incidence of Complication Depending on the Cannulation Site in US Guided Central Vein Catheterization

Conditions
-----------------
Brain Tumor

Intervention / Treatment
-----------------
* Procedure: Catheterization of subclavian vein
* Procedure: Catheterization of internal jugular vein


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Patients undergoing surgeries requiring central vein catheterizations for anesthetic management. Exclusion Criteria: Refuse hematologic disorder Anatomical abnormalities of central vein structure

Ages Eligible for Study
-----------------
Minimum Age: 15 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Supportive Care
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Active Comparator: Group SC<br>US guided subclavian vein catheterization | Procedure: Catheterization of subclavian vein<br>* Catheterization of subclavian vein<br>|
| Active Comparator: Group IJ<br>US-guided internal jugular vein catheterization | Procedure: Catheterization of internal jugular vein<br>* Catheterization of internal jugular vein<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| complication | any one of arterial puncture, hematoma, pneumothorax, hemothorax | during central vein catheterization and operation day | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Access time | from penetration of skin to aspiration of venous blood into the syringe | during central venous catheterization | 
| Number of attempts | once/twice/three times | during central venous catheterization | 
| catheter tip placement | After reviewing the postoperative chest X ray film, we will check the position of the central venous catheter tip. The possible pisition of catheter tip is as follows: (1) Superior vena cava and Rirht Atrium junction (2)Right internal jugular vein (3)Left Internal jugular vein (4)Right Axillary vein (5)Lt. Axillary vein | postoperative 1 day | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
open heart surgery, lung surgery, spine surgery, hepatobiliary surgery
Improved Use of Antibiotic Guidelines in Hospital Environment

Study Overview
=================
Brief Summary
-----------------
The purpose of this study is to determine if the use of antibiotic guidelines and thus antibiotics can be improved through a description of possible barriers leading to tailored interventions.

Official Title
-----------------
Improved Use of Antibiotic Guidelines in in Hospital Environment: Research on an Implementation Model and the Role of the Hospital Pharmacist.

Conditions
-----------------
Community-Acquired Pneumonia

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Diagnosed community-acquired pneumonia (CAP) Diagnosed community-acquired pyelonephritis Exclusion Criteria: CAP: hospital-acquired pneumonia; patients transferred from other hospital; death within 24h, aspiration pneumonia, immunocompromised status, palliative status, admission due to social reasons Pyelonephritis: urinary tract with functional or physical abnormalities, urinary catheterisation, pregnancy, (immunocompromised status, palliative status, admission due to social reasons and history of renal transplant.

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------
What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Time series, Implementation
Muscular and Metabolic Adaptations to Exercise to Benefit High-Risk Workforce

Study Overview
=================
Brief Summary
-----------------
The purpose of this study is to investigate the effects of three different exercise programs (e.g. low-intensity, medium-intensity, high-intensity) administered for six months on health-related physical fitness, biochemical variables and general health outcomes in high-risk employees, with about 2000 volunteers will participate in the randomized and repeated-measure study.

Detailed Description
-----------------
Exercise programs (e.g. low-intensity, medium-intensity, high-intensity) consist of aerobic workout, strength training and flexibility exercise, with different program has different intensity, volume, frequency and duration of exercise.

Official Title
-----------------
The Effects of Medium-Term Exercise Program on Health-Related Physical Fitness and Biochemical Outcomes in High-Risk Employees

Conditions
-----------------
Sedentary Lifestyle

Intervention / Treatment
-----------------
* Procedure: Exercise 1
* Procedure: Exercise 2
* Procedure: Exercise 3


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: over 18 years of age Exclusion Criteria: no diseases of musculoskeletal system

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Single


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: Exercise 1<br>Low-intensity, low-volume cardiorespiratory exercise and strength training | Procedure: Exercise 1<br>* Low-intensity, low-volume cardiorespiratory exercise and strength training<br>|
| Experimental: Exercise 2<br>Medium-intensity, medium-volume cardiorespiratory exercise and strength training | Procedure: Exercise 2<br>* Medium-intensity, Medium-volume cardiorespiratory exercise and strength training<br>|
| Experimental: Exercise 3<br>High-intensity, High-volume cardiorespiratory exercise and strength training | Procedure: Exercise 3<br>* High-intensity, High-volume cardiorespiratory exercise and strength training<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Cardiorespiratory endurance |  | Baseline and 6 months after intervention | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Muscular endurance |  | Baseline and 6 months after intervention | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Health-Related Physical Fitness, Aerobic Endurance, Muscular Endurance, Flexibility
Research on the Value of Genomics Research Based on Ultrasound Endoscopic Biopsy in the Differential Diagnosis and Prognostic Evaluation of Pancreatic Occupancy

Study Overview
=================
Brief Summary
-----------------
To clarify the value of genomic testing in the clinical diagnosis or prognosis of pancreatic space occupation, provide a basis for the selection of clinical diagnosis methods for pancreatic space occupation, optimize clinical management strategies, and improve the prognosis of patients.

Official Title
-----------------
Research on the Value of Genomics Research Based on Ultrasound Endoscopic Biopsy in the Differential Diagnosis and Prognostic Evaluation of Pancreatic Occupancy

Conditions
-----------------
Pancreatic Space Occupying

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Age 18-85, no gender limit Imaging examinations suggest that the clear pancreas has clear space-occupying lesions Admitted to our department, ready to undergo endoscopic ultrasound biopsy to confirm the diagnosis Exclusion Criteria: There are contraindications for endoscopic ultrasound biopsy Failed to join the group or refused follow-up due to various reasons

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 85 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Benign pancreatic space occupying group<br> | |
| Malignant pancreatic space occupying group<br> | |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Differential microRNA detected by sequencing | The diagnosis of microRNA in pancreatic space occupying | June 2023 | 
| Differential mRNA detected by sequencing | The diagnosis of mRNA in pancreatic space occupying | June 2023 | 
| Differential lncRNA detected by sequencing | The diagnosis of lncRNA in pancreatic space occupying | June 2023 |
Longitudinal Analysis of the Vaginal Microbiome

Study Overview
=================
Brief Summary
-----------------
This is a longitudinal, observational study with the goal of understanding vaginal microbiome changes both within a single day and across a menstrual cycle. The study will be composed of at least 10 women that have regular menstrual cycles and are 18 years of age or older. This study is direct to participant and will NOT utilize clinical sites.

Detailed Description
-----------------
Eligible women will be recruited into the study. They will be consented and asked to complete a health questionnaire. On six separate days during two menstrual cycles, they will be asked to collect vaginal swab samples (total of 12). For each sample collection, they will answer the sample collection questionnaire. Samples will be returned to Viome labs for analysis.

Official Title
-----------------
Longitudinal Analysis of the Vaginal Microbiome

Conditions
-----------------
Vaginal Microbiome

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Biological sex is female Willing to collect own vaginal samples Willing to answer health questions Experience menstrual cycles regularly (a monthly cycle) Exclusion Criteria: Pregnant Antibiotic use in the past 3 months

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
Female

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------
What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Identification of vaginal microbial taxonomy | A vaginal metatranscriptomic test will be used to analyze the vaginal microbiome taxonomy | 1 year | 
| Identification of vaginal microbial functions | A vaginal metatranscriptomic test will be used to analyze the vaginal microbiome functions | 1 year | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
vaginal pH, vaginal microbiome, menstrual cycle
Molecular Stethoscope

Study Overview
=================
Brief Summary
-----------------
The study aims to provide a more complete characterization and understanding of the genetic causes of and tumor DNA detection potential in colorectal cancer. Ultimately findings of this study will be used to develop early detection tests for colorectal cancer that are minimally invasive (based on a blood test). It is hoped that reliable, minimally invasive, early detection methods will lead to improved screening rates, increased screening safety, longer colorectal cancer survival, and overall cost savings. In order to assess the test's ability to detect tumor DNA, 25 participants with known colorectal cancer who will be undergoing surgical resection of the colon as part of their clinical care will be recruited. The investigators will collect blood from participants prior to surgery, tumor and normal tissue removed during surgery, a series of blood samples after surgery for up to one year and relevant medical records. DNA variants identified in blood will be compared against tissue samples. Serial samples will be analyzed to assess the variance in amount of circulating tumor DNA across time with standard treatment.

Official Title
-----------------
Molecular Stethoscope for Colon Cancer Detection

Conditions
-----------------
Colonic Neoplasms

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Colorectal cancer sent for surgical colonic resection (all stages) OR High risk adenoma sent for surgical colonic resection Exclusion Criteria: Chemotherapy before surgical treatment Invasive procedure resulting in damage to tissue (e.g., surgery, biopsy, thermal ablation) in the 7 days prior to baseline (pre-surgical) blood collection Radiation therapy before surgical treatment Bone marrow transplant

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 100 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| All participants<br>All subjects enrolled in the study will provide tumor and normal tissue and blood samples. | |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Determining sensitivity of assay in known cancer patients | The sensitivity (% positive out of all diseased patients) of circulating tumor DNA detection from the blood samples will be calculated against the gold standard of surgical pathology reports in this pilot group of patients with known colorectal cancer. | 2 years |